🚀 VC round data is live in beta, check it out!
Etropal Valuation Multiples
Discover revenue and EBITDA valuation multiples for Etropal and similar public comparables like BioRegenx, Ortivus, Balsm Alofoq, iZafe Group and more.
Etropal Overview
About Etropal
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
Founded
1976
HQ
Employees
168
Website
Sectors
Financials (FY)
EV
$16M
Etropal Financials
Etropal reported last fiscal year revenue of $10M and EBITDA of $748K.
In the same fiscal year, Etropal generated $3M in gross profit, $748K in EBITDA, and $54K in net income.
Etropal P&L
In the most recent fiscal year, Etropal reported revenue of $10M and EBITDA of $748K.
Etropal expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $10M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $3M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 30% | XXX | XXX | XXX |
| EBITDA | — | XXX | $748K | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 8% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 4% | XXX | XXX | XXX |
| Net Profit | — | XXX | $54K | XXX | XXX | XXX |
| Net Margin | — | XXX | 1% | XXX | XXX | XXX |
| Net Debt | — | — | $3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Etropal Stock Performance
Etropal has current market cap of $13M, and enterprise value of $16M.
Market Cap Evolution
Etropal's stock price is $2.67.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16M | $13M | 0.4% | XXX | XXX | XXX | $0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEtropal Valuation Multiples
Etropal trades at 1.7x EV/Revenue multiple, and 21.8x EV/EBITDA.
Etropal Financial Valuation Multiples
As of March 25, 2026, Etropal has market cap of $13M and EV of $16M.
Equity research analysts estimate Etropal's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Etropal has a P/E ratio of 248.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13M | XXX | $13M | XXX | XXX | XXX |
| EV (current) | $16M | XXX | $16M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 21.8x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 49.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5.6x | XXX | XXX | XXX |
| P/E | — | XXX | 248.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 52.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Etropal Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Etropal Margins & Growth Rates
Etropal's revenue in the last fiscal year grew by 41%.
Etropal Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 41% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 11% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Etropal Public Comps
See public comps and valuation multiples for other Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BioRegenx | XXX | XXX | XXX | XXX | XXX | XXX |
| Ortivus | XXX | XXX | XXX | XXX | XXX | XXX |
| Balsm Alofoq | XXX | XXX | XXX | XXX | XXX | XXX |
| iZafe Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Airway Medix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Etropal M&A Activity
Etropal acquired XXX companies to date.
Last acquisition by Etropal was on XXXXXXXX, XXXXX. Etropal acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Etropal
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEtropal Investment Activity
Etropal invested in XXX companies to date.
Etropal made its latest investment on XXXXXXXX, XXXXX. Etropal invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Etropal
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Etropal
| When was Etropal founded? | Etropal was founded in 1976. |
| Where is Etropal headquartered? | Etropal is headquartered in Bulgaria. |
| How many employees does Etropal have? | As of today, Etropal has over 168 employees. |
| Is Etropal publicly listed? | Yes, Etropal is a public company listed on Bulgarian Stock Exchange. |
| What is the stock symbol of Etropal? | Etropal trades under ETR ticker. |
| When did Etropal go public? | Etropal went public in 2007. |
| Who are competitors of Etropal? | Etropal main competitors are BioRegenx, Ortivus, Balsm Alofoq, iZafe Group. |
| What is the current market cap of Etropal? | Etropal's current market cap is $13M. |
| What is the current revenue of Etropal? | Etropal's last fiscal year revenue is $10M. |
| What is the current EV/Revenue multiple of Etropal? | Current revenue multiple of Etropal is 1.7x. |
| Is Etropal profitable? | No, Etropal is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.